Abstract Background and Aims Mental health challenges such as depression, anxiety, and existential distress are common among individuals with terminal illness. Preliminary evidence suggests that death acceptance may protect against these issues, but there is limited research on the role of psychedelic-assisted therapy in fostering death acceptance. This scoping review aims to explore the...
Background: Conventional psychological and pharmacological substance abuse treatments are limited to moderate effect sizes and fail to magnify outcomes when combined. Analog psychedelic agents N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) show therapeutic potential for treatment-resistant psychiatric disorders including substance addictions. Methods: This...
Psychedelic-assisted therapy for PTSD tends to produce mild, transient adverse effects, but concerns about long-term safety and inconsistent reporting of adverse events highlight the need for further research.
PsychedelicsApril 2, 2026Dalia N. Balsamo, Prachi Garodia, Nima Fayazmanesh et al.
The integration of music into psychedelic-assisted therapy (PAT) has emerged as a key aspect of therapeutic psychedelic experiences, providing a significant enhancement in emotional processing and insight generation. This review examines the interplay between music and psychedelics, and explores how this integration can enhance therapeutic outcomes in various conditions with a broader emphasis...
Research on the therapeutic effects of psychedelics in psychiatry, commonly referred to as Psychedelic-Assisted Therapy (PAT), has expanded substantially in recent years. The context-dependent nature of psychedelics has sparked discussion about the importance of the psychotherapeutic environment in achieving beneficial outcomes. This study explores the contribution of psychotherapeutic factors...
Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...
Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...
Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions. Because PAT is effectively always open label, treatment results should be compared with those of open-label traditional antidepressants (TADs), so potential benefits associated with patients knowing their treatment is equal between...
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine...
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.